Microbix Biosystms (MBX) AI Stock Analysis

• Market Cap: C$35.58M
• Dividend Yield: N/A
• Average Volume (3M): 57.61K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: -9.54%
• EPS Growth: -105.12%
• Country: CA
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 139,512,480
• 10 Day Avg. Volume: 59,614
• 30 Day Avg. Volume: 57,610
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 1.80
• P/FCF Ratio: 18.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: C$0.50 ▲(108.33% Upside)

Microbix Biosystems' overall stock score is primarily influenced by its strong financial performance and stability, despite recent revenue challenges. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. The earnings call reflects both immediate challenges and potential for future growth, balancing the overall outlook.

Positive Factors

Product Line Expansion

The introduction of the QUANTDx product line, which integrates earlier in assay development and sells at higher prices, positions Microbix to enhance its market presence and drive revenue growth, reflecting a strategic expansion of its product offerings.

Financial Stability

A strong balance sheet with a high current ratio and low debt-to-equity ratio provides Microbix with financial resilience, enabling it to withstand temporary setbacks and invest in growth opportunities.

Growth in Core Segments

The robust growth in the QAPs and antigen segments, despite setbacks from major clients, underscores the strength and potential of Microbix's core business areas, supporting long-term revenue expansion.

Negative Factors

Revenue Challenges

Significant revenue declines from key clients highlight customer concentration risks, which can impact financial performance and necessitate diversification to stabilize future earnings.

Margin Pressures

Persistent margin pressures from fixed costs and product mix challenges could constrain profitability, requiring strategic adjustments to improve cost efficiency and product offerings.

Market Uncertainty in China

The decline in demand for respiratory infection testing in China introduces uncertainty in a key market, potentially affecting future revenue streams and necessitating strategic market adjustments.

Microbix Biosystms Business Overview & Revenue Model

Company Description

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Microbix Biosystems generates revenue primarily through the sale of its proprietary products, which include antigens and quality control materials used in diagnostic testing. Their revenue model is based on direct sales to diagnostic laboratories, pharmaceutical companies, and other healthcare providers. Key revenue streams include the sale of viral and bacterial antigens, which are vital for various tests, as well as quality control products that ensure the reliability of laboratory results. Additionally, the company benefits from partnerships with other biotech firms and research institutions, which can lead to collaborative projects and increased sales opportunities. Significant contracts and collaborations with major players in the diagnostics industry further enhance its revenue potential, allowing Microbix to expand its market presence and leverage its product offerings effectively.

Microbix Biosystms Financial Statement Overview

Summary

Microbix Biosystems shows strong revenue growth and improved profitability margins. The balance sheet is stable with manageable leverage, and cash flows are increasingly positive. However, challenges in maintaining revenue momentum and potential liquidity risks due to past negative free cash flow are concerns.

Income Statement

Microbix Biosystems has shown strong revenue growth from 2020 to 2024, with a significant improvement in net profit margins. The company achieved a positive net income in recent years, contrasting with previous losses. Notably, the TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 56.1% and a net profit margin of 8.3%, pointing to improved profitability. However, the recent decline in total revenue from the annual report suggests potential challenges in maintaining revenue momentum.

Balance Sheet

The company's balance sheet reflects a stable equity base, with a notable decrease in debt levels over the years. The debt-to-equity ratio shows a moderate level of leverage, which is manageable. The equity ratio has been improving, indicating a stronger financial position. However, the biotechnology industry is capital intensive, and continuous investment might affect leverage ratios.

Cash Flow

Microbix Biosystems has demonstrated an improvement in operating cash flow, achieving positive free cash flow in the latest periods. The free cash flow to net income ratio suggests healthy cash generation relative to profits. However, past periods of negative free cash flow highlight potential liquidity risks if revenue declines or investment increases unexpectedly.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.13M	25.39M	16.51M	19.08M	18.59M	10.52M
Gross Profit	11.79M	15.39M	7.48M	11.12M	11.04M	4.66M
EBITDA	2.47M	6.21M	1.96M	3.73M	5.66M	-2.91M
Net Income	-324.83K	3.52M	-39.48K	1.79M	1.63M	-6.23M
Balance Sheet
Total Assets	38.26M	38.10M	35.65M	33.15M	28.83M	15.60M
Cash, Cash Equivalents and Short-Term Investments	12.10M	12.96M	11.61M	13.49M	9.99M	92.66K
Total Debt	6.41M	6.40M	6.65M	5.82M	7.74M	6.17M
Total Liabilities	8.94M	9.80M	11.03M	8.21M	10.27M	8.98M
Stockholders Equity	29.32M	28.30M	24.62M	24.94M	18.56M	6.62M
Cash Flow
Free Cash Flow	-270.79K	2.44M	-2.11M	1.44M	804.20K	-805.34K
Operating Cash Flow	601.69K	4.35M	-1.09M	3.47M	2.11M	8.57K
Investing Cash Flow	-872.48K	-1.91M	-1.02M	-2.03M	-622.34K	-813.91K
Financing Cash Flow	-437.09K	-1.08M	229.21K	2.06M	8.41M	802.43K

Microbix Biosystms Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MBX, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.25, below the 50-day MA of 0.25, and below the 200-day MA of 0.32, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 20.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MBX.

Microbix Biosystms Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	74 Outperform	C$53.19M	22.99	9.01%	―	13.00%	―
MBX	59 Neutral	C$35.58M	-134.21	-1.13%	―	-9.54%	-105.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONC	43 Neutral	―	―	―	―	―	―
MIR	41 Neutral	C$52.32M	-11.19	―	―	-33.66%	-48.89%
SVA	33 Underperform	C$44.37M	―	―	―	―	55.88%
HBP	33 Underperform	C$152.02M	-21.22	-67.18%	―	―	52.62%

Microbix Biosystms Corporate Events

Microbix Biosystems to Engage with Investors at Muskoka Capital Event

Microbix Biosystems Inc. announced its participation in the Muskoka Capital Event, where its CEO and COO will engage in one-on-one meetings with growth-oriented investors. This event is an opportunity for Microbix to enhance its visibility among investors and potentially secure financing and market support. The company’s participation underscores its proactive approach in engaging with the investment community to bolster its market presence and operational growth.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix and EMQN Launch EQA Program for Genetic Testing in Clopidogrel Dosing

Microbix Biosystems Inc. and EMQN CIC have launched a new external quality assessment (EQA) program to improve the accuracy of genetic testing for patients prescribed the anti-clotting drug Clopidogrel. This initiative aims to ensure that patients with gene variants affecting drug metabolism receive appropriate dosing, thereby reducing the risk of life-threatening bleeding or clots. The program utilizes Microbix’s quality assessment products to help laboratories maintain testing proficiency, ultimately aiding physicians and pharmacists in making informed prescription decisions. This collaboration marks Microbix’s second venture into supporting genetic test accuracy, complementing its established roles in infectious diseases and oncology.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix and Labquality Launch EQA Program for Accurate HPV-Related Cancer Diagnosis

Microbix Biosystems Inc. and Labquality Oy have launched a novel external quality assessment (EQA) program to help clinical laboratories accurately identify head and neck cancers associated with HPV. This initiative addresses a critical need in the diagnostics industry by providing proficiency testing for labs, using Microbix’s QAPs that emulate clinical specimens. The program aims to enhance diagnostic accuracy, reduce subjectivity in test interpretation, and prevent inappropriate treatment decisions, thereby supporting labs in achieving high-quality assurance standards.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Hosts Ontario Minister to Showcase Biotech Innovations

Microbix Biosystems Inc. recently hosted Ontario’s Minister of Public and Business Service Delivery, Stephen Crawford, at its biotechnology manufacturing facilities in Mississauga. The visit highlighted the company’s role in advancing next-generation diagnostics to improve health outcomes and reduce healthcare costs. Supported by Ontario’s government with significant grant funding, Microbix has developed state-of-the-art manufacturing capabilities and world-leading healthcare products. The company’s operations contribute to economic growth and job creation in Ontario, emphasizing its commitment to innovation and quality in the life sciences sector.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems Navigates Challenges with Strategic Growth

Microbix Biosystems’ latest earnings call painted a picture of a challenging quarter, marked by significant revenue setbacks with two major clients. This led to the weakest performance in three years. Despite these hurdles, the company remains financially stable, with promising new product developments and ongoing progress in the Kinlytic project. The company is poised for future growth, building on strong financials and expanding product lines.

Microbix Biosystems Faces Revenue Decline Amid Market Challenges

Microbix Biosystems reported a challenging third quarter for fiscal 2025, with revenues falling to $3.5 million, a 31% decrease from the previous year, primarily due to reduced sales in China and the cancellation of test-development programs by a key customer. Despite a strong cash position, the company experienced a net loss of $1.64 million, driven by weaker gross margins and increased operating expenses. The year-to-date performance also saw a decline in revenues and margins, leading to an operating loss, although antigen sales showed some growth. The company’s financial ratios improved, indicating a strong liquidity position, but the outlook remains cautious due to ongoing challenges in key markets.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems to Announce Q3 Fiscal 2025 Results

Microbix Biosystems Inc. announced the upcoming release of its Q3 fiscal 2025 financial results, scheduled for August 14, 2025, followed by a webinar discussion with the company’s executives. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.